8-K: MetaVia Announces Positive Phase 2a Trial Results for MASH Treatment DA-1241

MetaVia's DA-1241 shows positive top-line results in a Phase 2a clinical trial for MASH, demonstrating significant reductions in key liver and metabolic markers.

Summary

• MetaVia Inc. has announced positive top-line results from its Phase 2a clinical trial of DA-1241 for patients with presumed metabolic dysfunction-associated steatohepatitis (MASH).
• The trial included two parts: one testing DA-1241 against a placebo, and another testing DA-1241 in combination with sitagliptin.
• The 100mg dose of DA-1241 showed statistically significant reductions in alanine transaminase (ALT) levels at weeks 4 and 8, and a near statistically significant reduction at week 16.
• Statistically significant improvements were also observed in secondary endpoints, including reductions in controlled attenuation parameter (CAP) scores and hemoglobin A1C (HbA1c) levels.
• The study involved 109 patients, with 95 completing the dosing period.
• DA-1241 was well-tolerated, with mostly mild adverse events and no serious drug-related adverse events.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results with statistically significant improvements in key metrics and good tolerability, suggesting a strong potential for the drug. The sentiment is very positive.

Positives

• The trial demonstrated that DA-1241 has a direct hepatic action in addition to its glucose-lowering effect.
• The 50mg dose of DA-1241 showed a statistically significant improvement in the normalization of ALT levels compared to placebo.
• The results suggest that DA-1241 could be a safe and effective treatment option for MASH.
• The study showed positive trends in other liver enzymes such as AST and GGT.

Negatives

• The 50mg dose of DA-1241 did not show statistically significant reductions in ALT levels at weeks 4, 8 and 16.
• The combination of DA-1241 100mg and sitagliptin did not show statistically significant reductions in ALT levels at weeks 4, 8 and 16.

Risks

• The forward-looking statements are subject to risks and uncertainties, including the ability to execute on the commercial strategy and obtain regulatory approval.
• There are risks associated with the cooperation of contract manufacturers and clinical study partners.
• Potential negative interactions between MetaVia's product candidates and other products are a risk.
• The company's ability to initiate and complete clinical trials on a timely basis is a risk.
• The company's ability to recruit subjects for its clinical trials is a risk.
• There is a risk that the results from clinical trials may not be consistent with pre-clinical and previous clinical trials.
• Changes in applicable laws or regulations could impact the company.
• Changes to MetaVia's stock price could impact the terms of the license agreement and any future fundraising.

Future Outlook

MetaVia expects to have an end of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in the first half of 2025 and continues to explore other combination therapies for DA-1241.

Management Comments

• Achieving the primary endpoint of a reduction in ALT levels through direct hepatic effects, as well as notable secondary endpoints, including significantly lower HbA1C levels compared to the placebo, are extremely positive results for DA-1241, especially given the small study size, stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia.
• Based on this data, we continue to believe that the novel mechanism of action of DA-1241, addressing the inflammation linked to MASH, will result in a safe and effective treatment option for this disease.

Industry Context

The announcement is significant in the context of the growing need for effective treatments for MASH, a condition with limited therapeutic options. The positive results for DA-1241 position MetaVia as a potential player in the cardiometabolic disease space.

Comparison to Industry Standards

• The results of the DA-1241 trial are promising when compared to other MASH treatments in development, particularly in terms of the statistically significant reductions in ALT, CAP, and HbA1c.
• Companies like Madrigal Pharmaceuticals with their drug Resmetirom have shown positive results in MASH, but DA-1241's unique mechanism of action as a GPR119 agonist could offer a different approach.
• Other companies such as Intercept Pharmaceuticals with Obeticholic acid have also targeted MASH, but with different mechanisms and results, making DA-1241's profile potentially competitive.
• The trial's focus on both liver inflammation and metabolic markers like HbA1c is also notable, as many MASH treatments focus primarily on liver-specific outcomes.

Stakeholder Impact

• Shareholders are likely to react positively to the promising clinical trial results.
• Employees may be motivated by the positive progress of the company's drug development.
• Patients with MASH may have a new potential treatment option.
• The results could positively impact the company's relationships with suppliers and partners.

Next Steps

• MetaVia will submit additional findings for upcoming scientific conferences.
• The company plans to have an end of Phase 2 meeting with the FDA in the first half of 2025.
• Pre-clinical studies will continue to explore other combination therapies for DA-1241.

Key Dates

Keywords

MASH, DA-1241, GPR119 agonist, clinical trial, metabolic dysfunction-associated steatohepatitis, ALT, CAP score, HbA1c, liver inflammation, cardiometabolic diseases